science
science · EN
The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
36%
Guest openness
Selective
Sign up to generate a grounded pitch for Foundation Fighting Blindness.
Signup to Generate a PitchRecent episodes include "Emerging gene therapy for RDH12-associated Leber congenital amaurosis cleared for clinical trials" (23 October 2026, 2 minutes), "Eye on the Cure | Episode 104: Emerging XLRP gene therapy shows promising clinical trial results" (21 October 2026, 38 minutes), and "PRPH2 Workshop 2026: Day 1 Keynote, John Samuel" (5 October 2026, 33 minutes).
Foundation Fighting Blindness publishes roughly weekly, with episodes averaging 13 minutes across 275 episodes.
Booking probability for Foundation Fighting Blindness is 36%, and the host is rated Selective on guests. Foundation Fighting Blindness requires a Pod Score of 80 or higher. Foundation Fighting Blindness's contact route on record: verified email.
The strongest fits for Foundation Fighting Blindness are Scientific Research & Development and Health & Wellness Services. Foundation Fighting Blindness has a science audience and around 6,400 subscribers on YouTube.
Foundation Fighting Blindness is a science podcast with 275 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Foundation Fighting Blindness
An emerging gene therapy treatment for Leber congenital amaurosis (LCA) received the green light from the U.S. Food and Drug Administration to proceed with clinical trials in people, bringing it one step closer to...
Foundation Fighting Blindness
Host Maddie Mossman talks with Dr. Daniel Chung, Chief Medical Officer of Beacon Therapeutics, about Laru-zova, an emerging treatment for X-linked retinitis pigmentosa. Based on encouraging clinical trial results...
Foundation Fighting Blindness
PRPH2 Workshop 2026: Day 1 Keynote – John Samuel by Foundation Fighting Blindness
Foundation Fighting Blindness
Opus Genetics has shared encouraging early results from its ongoing Phase 1/2 clinical trial for OPGx-BEST1, a potential one-time gene therapy for people with BEST1-related retinal disease. All five patients enrolled in...
Foundation Fighting Blindness
Beacon Therapeutics reported positive results from the Phase 3 pivotal trial of laru-zova, its potential gene therapy treatment for X-linked retinitis pigmentosa. A significant proportion of patients improved dim-light...
Foundation Fighting Blindness
The U.S. Food and Drug Administration accepted Dallas-based Nanoscope Therapeutics' biologics license application for MOGENRY, an emerging treatment for adults with retinitis pigmentosa and severe vision loss. The...
Foundation Fighting Blindness
Two non-profit professionals talk about plugging into community and finding low-vision resources through the Foundation
Foundation Fighting Blindness
Sumitomo Pharma America treated its first patient in a Phase 1/2a clinical trial for an emerging retinitis pigmentosa (RP) treatment called DSP-3077. The clinical trial plans to treat 12 adults with one of two different...
Foundation Fighting Blindness
Tarsus Pharmaceuticals announced plans to acquire Alkeus Pharmaceuticals, including its emerging oral treatment for Stargardt disease, gildeuretinol (ALK-001), in a deal valued up to $800 million. Stargardt disease is...
Foundation Fighting Blindness
In Europe, Science Corporation has commercially launched PRIMA, a retinal implant designed to restore central vision in people with geographic atrophy (GA). The treatment has been shown in clinical trials to restore...
Foundation Fighting Blindness
Belite Bio’s tinlarebant could become the first-ever approved treatment for Stargardt disease
Foundation Fighting Blindness
Dr. Alicia Kemble explains how the Foundation is using venture philanthropy to drive treatments for inherited retinal diseases even closer to the finish line.
Foundation Fighting Blindness
Sepul Bio recently announced that it completed enrollment of its Phase 2b safety and efficacy clinical trial for ultevursen – an investigational RNA therapy to treat patients who have retinitis pigmentosa (RP)...
Foundation Fighting Blindness
FDA approves Lumvoa, a new treatment for thyroid eye disease by Foundation Fighting Blindness
Foundation Fighting Blindness
Belite Bio submits new drug application to FDA for its Stargardt treatment by Foundation Fighting Blindness
Foundation Fighting Blindness
New host Maddie Mossman interviews retinal surgeon Dr. Staropoli, the first medical doctor to win a NASCAR race.
Foundation Fighting Blindness
Promising oral treatment moves closer for Stargardt patients.
Foundation Fighting Blindness
2020 Llura Liggett Gund Award recipient honored for pioneering gene therapy that transformed vision research
Foundation Fighting Blindness
Data monitoring committee recommends proceeding with registration-enabling study for ATSN-201
Foundation Fighting Blindness
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) by Foundation Fighting Blindness
Recent guests on Foundation Fighting Blindness. Study who booked and why before you pitch.
Former Prosecutor for Santa Clara County, Beacon Therapeutics
writer, sexuality counselor, pelvic physical therapist, AhHa!Broadway Inc.
leadership development expert, The Learn It All Leader
Chief Scientific Officer, Hamilton County Economic Inclusion and Equity Department
PitchCentric classifies Foundation Fighting Blindness under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
